Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases (OPTIMAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04001725
Recruitment Status : Recruiting
First Posted : June 28, 2019
Last Update Posted : November 13, 2019
Sponsor:
Collaborator:
University of Milan
Information provided by (Responsible Party):
Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Brief Summary:
This is a monocentric, open label, randomized Phase II study in patients with brain metastasis from melanoma, lung or breast cancer, who require treatment with high-dose dexamethasone, as defined as a minimum of 8 mg daily based on the clinician judgment, for at least three weeks, with or without radiation therapy. The aim is to investigate the metformin efficacy in preventing the onset of glucocorticoid-induced diabetes and other metabolic perturbations in patients with brain metastases from melanoma, lung or breast cancer.

Condition or disease Intervention/treatment Phase
Brain Metastases Melanoma Lung Cancer Breast Cancer Drug: Dexamethasone Drug: Metformin Phase 2

Detailed Description:
The study will be conducted in approximately 110 adult patients. aim of the study is to evaluate the effect of oral metformin in preventing GC-induced alterations of systemic metabolism, and in particular GC-induced diabetes. Other clinical objectives of the study consist in investigating the impact of metformin on precocious mortality, deterioration of ECOG PS and local (brain) disease control rate at one month. As an exploratory analysis, the effect of dexamethasone plus/minus metformin on other metabolites or growth factors (including amino acids, fatty acids, ketone bodies, IGF-1), as well as on the number, activation status and metabolism of peripheral blood immune cell populations will be evaluated

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 110 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Eligible patients will be randomized in a 1:1 ratio. Randomization will be stratified by means of minimization technique according to the following factors: primary tumor (melanoma versus lung versus breast cancer), dexamethasone dosage (8-12 mg vs >12 mg daily), baseline (pre-enrollment) fasting glycemia (< 100 versus 100-125 mg/dl). Patients randomized to the experimental arm will discontinue metformin after 30 days, unless diabetes has developed in the meanwhile and the physician believes that metformin is still required for its management. Patients randomized to the control arm who develop steroid-induced diabetes will be prescribed metformin, unless contraindicated, as the preferred therapy option for the management of hyperglycemia. In both treatment arms, dexamethasone will be administered until necessary and at the required dosage in the judgment of the treating physician.
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Melanoma, breAst or Lung Cancer Patients With Brain Metastases: the Phase II OPTIMAL Study
Actual Study Start Date : October 15, 2019
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : March 31, 2022


Arm Intervention/treatment
Active Comparator: A (Dexamethasone)
Patients subjected at a minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route (control arm). The total dose can either administered once a day or through a refracted schedule
Drug: Dexamethasone
A minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route, once or twice a day.

Experimental: B (Dexamethasone and Metformin)

Patients subjected at a minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route.The total dose can either administered once a day or through a refracted schedule.

The same patients subjected at a metformin. Metformin initial dosage will be 850 mg per day, and will be escalated based on patient tolerability up to a maximum of 2550 mg daily (experimental arm).

Drug: Dexamethasone
A minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route, once or twice a day.

Drug: Metformin
A minimum daily dosage of Dexamethasone 8 mg through the oral, intramuscular or intravenous administration route, once or twice a day and 2550 mg daily (maximum dose), oral administration (OS) of Metformin; starting dose will be 850 mg/day, to be progressively increased to 1700 mg/day on day 4 and 2550 mg/day on day 7, if well tolerated.
Other Name: METFORAL




Primary Outcome Measures :
  1. Metformin in preventing precocious (14 days) dexamethasone-induced diabetes [ Time Frame: 14 days ]
    To evaluate the efficacy of metformin in preventing precocious (14 days) dexamethasone-induced diabetes, as defined as fasting plasma glucose levels ≥ 126 mg/dl, in patients with brain metastases from melanoma, lung or breast cancer.


Secondary Outcome Measures :
  1. Dexamethasone-induced diabetes at 30 days [ Time Frame: 30 days ]
    To study the efficacy of metformin in preventing dexamethasone-induced diabetes at 7 and 30 days after dexamethasone initiation, as defined as fasting plasma glucose levels ≥ 126 mg/dl, in patients with brain metastases from melanoma, lung or breast

  2. Short-term mortality [ Time Frame: 90 days ]
    To evaluate the efficacy of metformin in modifying short-term mortality (3 months) in patients taking high-dose dexamethasone

  3. Brain local control rate of disease [ Time Frame: 30 days ]
    To evaluate the efficacy of metformin in modifying the local disease control rate (brain) in patients treated with radiation therapy (RT) plus dexamethasone at 1 month

  4. Patient ECOG performance status (PS) [ Time Frame: 30 days ]
    To test the impact of metformin on precocious modifycation of patient ECOG Performance Status (PS) at 1 month after initiation of dexamethasone therapy.

  5. Patient Quality of Life (QoL) [ Time Frame: 30 days ]
    Patient QoL will be evaluated through the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) C-30 version 3.0. The EORTC QLQ.C30 instrument will be scored according to the EORTC guidelines.

  6. Absolute counts of immune cell populations [ Time Frame: 2 years ]
    To investigate the potential impact of metformin on absolute counts of immune cell populations

  7. Relative counts of immune cell populations [ Time Frame: 2 years ]
    To investigate the potential impact of metformin on relative counts and activation status of activated antitumor lymphocytes

  8. Activation status of immune cell populations [ Time Frame: 2 years ]
    To investigate the potential impact of metformin on activated antitumor lymphocytes

  9. Plasma lipids profile [ Time Frame: 14 days ]
    To study the effect of metformin in modifying the plasma lipid profile at 14 days after treatment initiation

  10. Plasma lipids profile [ Time Frame: 30 days ]
    To study the effect of metformin in modifying the plasma lipid profile at 30 days after treatment initiation

  11. Systemic inflammatory parameters [ Time Frame: 2 years ]
    To investigate the effect of metformin on systemic plasma cytokines (G-CSF, GM-CSF, CCL2, VEGFA)

  12. GC-induced changes in gut microbiota populations [ Time Frame: 30 days ]
    To evaluate the impact of high-dose GCs on gut microbiota populations (30 days)

  13. Metformin-induced changes in gut microbiota populations [ Time Frame: 30 days ]
    To evaluate the impact of metformin on gut microbiota populations (30 days)

  14. Amino acid profile [ Time Frame: 14 days ]
    To study the effect of metformin in modifying the plasma amino acid profile at 14 days after treatment initiation



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years and ≤ 75 years
  2. Histologically confirmed diagnosis of melanoma, lung (SCLC or NSCLC) or breast cancer
  3. Recent (28 days), radiologically documented (contrast-enhanced CT or MRI) diagnosis of measurable brain metastases requiring treatment with high-dose dexamethasone (at least 8 mg daily for at least 21 days) plus/minus radiation therapy (RT).
  4. Any previous or ongoing antitumor systemic therapy; patients who have never received previous systemic therapy can be also included.
  5. Fasting glycemia < 126 mg/dl at the baseline evaluation or random glycemia of less than 200 mg/dl if the patient has not fasted for at least 8 hours before blood sampling.
  6. Adequate blood tests:

    • Hemoglobin ≥ 9 g/dl
    • Absolute neutrophil count (ANC) in the range between 1.5-10 x 103/μl
    • Total bilirubin ≤ 1.5 times the upper normal limit (UNL). For patients with Gilbert syndrome or known liver metastases, bilirubin levels ≤ 3 times the UNL are considered acceptable
    • AST, ALT ≤ 3 times the UNL
    • Alkaline phosphatase ≤ 2.5 times the UNL
    • Serum creatinine concentration ≤ 1.5 x UNL
  7. ECOG Performance Status ≤ 2
  8. Life expectancy > 6 weeks
  9. Written informed consent
  10. Ability to swallow metformin tablets
  11. Patients of female gender with the potential of childbearing (neither surgically sterile nor 2 years postmenopausal) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for at least 60 days after study conclusion. Acceptable methods of contraception include double barrier method [i.e. condom and occlusive cap (diaphragm or cervical vault caps)] spermicide, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, or injected) in conjunction with a barrier method.
  12. Patients of male gender having female partners with childbearing potential must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 60 days after participation in the study

Exclusion Criteria:

  1. Leptomeningeal carcinomatosis, either radiologically documented or cytologically confirmed
  2. History of brain metastases
  3. Diagnosis of other malignancies in the last 5 years, except for superficial, radically treated basal cell carcinomas of the skin or in situ carcinomas of the cervix
  4. Previous or current use of metformin
  5. Ongoing therapy with systemic glucocorticoids at a dosage that is higher than 10 mg prednisone equivalent. Previous GC treatment is allowed if stopped at least 2 months before enrollment. Inhaled or topical steroids are permitted.
  6. Diagnosis of Type 1 or Type 2 diabetes mellitus
  7. Known history of HBV- or HCV-related infection
  8. Known liver cirrhosis, even in the absence of significant alterations in blood tests
  9. Clinically uncontrolled disorders of the lung, kidney, liver or cardio-vascular apparatus
  10. Known history of HIV infection
  11. Serious neurological or psychiatric disorders
  12. Absence of a caregiver for patients with an ECOG performance status of 2
  13. Pregnancy or lactation
  14. Body mass index < 18.5 kg/m2
  15. Past or current alcohol abuse (> 36 grams/day for men and 24grams/day for women)
  16. Documented metabolic acidosis from any cause in the last 5 years
  17. History of allergy or hypersensitivity to study drug components

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04001725


Contacts
Layout table for location contacts
Contact: Filippo De Braud, Professor 0039 02 23902148 Filippo.DeBraud@istitutotumori.mi.it
Contact: Claudio Vernieri, MD 0039 02 23903066 Claudio.Vernieri@istitutotumori.mi.it

Locations
Layout table for location information
Italy
Fondazione IRCCS Istituto Nazionale dei Tumori Recruiting
Milan, Italy, 20133
Contact: Claudio Vernieri, M.D., Ph.D.    +39 02 23903066    claudio.vernieri@istitutotumori.mi.it   
Sponsors and Collaborators
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
University of Milan
Investigators
Layout table for investigator information
Principal Investigator: Filippo De Braud, Professor Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Publications:
Pusceddu S, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, Ibrahim T, Brizzi MP, Campana D, Faggiano A, Giuffrida D, Rinzivillo M, Cingarlini S, Aroldi F, Antonuzzo L, Berardi R, Catena L, De Divitiis C, Ermacora P, Perfetti V, Fontana A, Razzore P, Carnaghi C, Davì MV, Cauchi C, Duro M, Ricci S, Fazio N, Cavalcoli F, Bongiovanni A, La Salvia A, Brighi N, Colao A, Puliafito I, Panzuto F, Ortolani S, Zaniboni A, Di Costanzo F, Torniai M, Bajetta E, Tafuto S, Garattini SK, Femia D, Prinzi N, Concas L, Lo Russo G, Milione M, Giacomelli L, Buzzoni R, Delle Fave G, Mazzaferro V, de Braud F. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. Gastroenterology. 2018 Aug;155(2):479-489.e7. doi: 10.1053/j.gastro.2018.04.010. Epub 2018 Apr 13.

Layout table for additonal information
Responsible Party: Filippo de Braud, Professor, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
ClinicalTrials.gov Identifier: NCT04001725    
Other Study ID Numbers: INT31/19
B43C17000350001 ( Other Grant/Funding Number: Italian Minister of Health (5x1000 year 2014) )
2019-000105-73 ( EudraCT Number )
First Posted: June 28, 2019    Key Record Dates
Last Update Posted: November 13, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano:
Metformin
Dexamethasone
Diabetes
Glucocorticoids
Phase II
Tumor
Immune system
Immunological Effects
Metabolic Effects
Anticancer Effects
Randomization
Quality of Life
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Melanoma
Neoplasm Metastasis
Brain Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplastic Processes
Pathologic Processes
Central Nervous System Neoplasms
Nervous System Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Metformin
Dexamethasone
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs